ArticleCureus2026
Red Breast Syndrome and Early Postoperative Complications in Immediate Prepectoral Implant-Based Reconstruction Using Braxon® Acellular Dermal Matrix: A Retrospective Cohort Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRed breast syndrome (RBS) is a self-limited, non-infectious erythema historically linked to acellular dermal matrices (ADMs) in breast reconstruction. Recent reports suggest a declining incidence, potentially related to ADM advancements. This study evaluates the contemporary incidence of RBS and postoperative complications in patients undergoing immediate prepectoral reconstruction with a specific porcine ADM (Braxon®, Decomed s.r.l., Venice, Italy).
methodsThis is a retrospective cohort study of all consecutive patients who underwent immediate prepectoral breast reconstruction with ADM (Braxon®) at our institution. Patients were identified from a prospectively maintained database. The study included all procedures performed between August 1, 2020, and October 31, 2024 (the data cutoff date for analysis). Data on demographics, surgical details, and postoperative outcomes were collected. Complications were classified as minor (managed conservatively) or major (requiring reoperation). RBS was defined by strict clinical criteria excluding infection. Univariate analysis assessed risk factors for complications.
resultsNo cases of RBS were observed (0/95, 0%). Early minor complications included seroma (7/95, 7.3%), skin necrosis (4/95, 4.2%), and infection (1/95, 1%). Major complications requiring reoperation occurred in 15.8% (15/95) of cases, with an overall implant loss rate of 13.7% (13/95). Preoperative radiotherapy significantly increased early complications (RR = 3.2, p = 0.013) and implant loss risk six-fold (RR = 6.17, p = 0.007). Postoperative radiotherapy was associated with higher capsular contracture rates (RR = 3.73, p = 0.008). Smoking, necrosis, infection, and dehiscence were significant predictors of implant loss (p < 0.05).
conclusionNotably, no cases of RBS were identified in this cohort, supporting the safety of Braxon® ADM in prepectoral reconstruction and contributing to evidence of its declining incidence. This absence may be attributed to specific ADM properties, surgical technique, and patient selection. However, radiotherapy and smoking remain critical, modifiable risk factors for implant-related complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.